Next Article in Journal
On Functional Module Detection in Metabolic Networks
Next Article in Special Issue
The Complex Role of Branched Chain Amino Acids in Diabetes and Cancer
Previous Article in Journal
Quantitative Determination of Common Urinary Odorants and Their Glucuronide Conjugates in Human Urine
Previous Article in Special Issue
A Review of Applications of Metabolomics in Cancer
Article Menu

Export Article

Open AccessArticle
Metabolites 2013, 3(3), 658-672;

Global Metabolomics Reveals Urinary Biomarkers of Breast Cancer in a MCF-7 Xenograft Mouse Model

Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Developmental Therapeutics Program, SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick, Frederick, MD 21702, USA
Author to whom correspondence should be addressed.
Received: 21 June 2013 / Revised: 2 August 2013 / Accepted: 2 August 2013 / Published: 7 August 2013
(This article belongs to the Special Issue Cancer Metabolomics)
Full-Text   |   PDF [950 KB, uploaded 8 August 2013]   |  


Global metabolomics analysis has the potential to uncover novel metabolic pathways that are differentially regulated during carcinogenesis, aiding in biomarker discovery for early diagnosis and remission monitoring. Metabolomics studies with human samples can be problematic due to high inter-individual variation; however xenografts of human cancers in mice offer a well-controlled model system. Urine was collected from a xenograft mouse model of MCF-7 breast cancer and analyzed by mass spectrometry-based metabolomics to identify metabolites associated with cancer progression. Over 10 weeks, 24 h urine was collected weekly from control mice, mice dosed with estradiol cypionate (1 mg/mL), mice inoculated with MCF-7 cells (1 × 107) and estradiol cypionate (1 mg/mL), and mice dosed with MCF-7 cells (1 × 107) only (n = 10/group). Mice that received both estradiol cypionate and MCF-7 cells developed tumors from four weeks after inoculation. Five urinary metabolites were identified that were associated with breast cancer; enterolactone glucuronide, coumaric acid sulfate, capric acid glucuronide, an unknown metabolite, and a novel mammalian metabolite, “taurosebacic acid”. These metabolites revealed a correlation between tumor growth, fatty acid synthesis, and potential anti-proliferative effects of gut microbiota-metabolized food derivatives. These biomarkers may be of value for early diagnosis of cancer, monitoring of cancer therapeutics, and may also lead to future mechanistic studies. View Full-Text
Keywords: metabolomics; biomarker; MCF-7; breast cancer; xenograft metabolomics; biomarker; MCF-7; breast cancer; xenograft

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Johnson, C.H.; Manna, S.K.; Krausz, K.W.; Bonzo, J.A.; Divelbiss, R.D.; Hollingshead, M.G.; Gonzalez, F.J. Global Metabolomics Reveals Urinary Biomarkers of Breast Cancer in a MCF-7 Xenograft Mouse Model. Metabolites 2013, 3, 658-672.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top